Table 1.
FLT3 mutational status and proliferation IC50 for TTT-3002 treatment of leukemia cell lines
| Cell line | FLT3 status | IC50 (nM) |
|---|---|---|
| Ba/F3-ITD | ITD | 0.62 |
| MV4-11 | ITD | <0.25 |
| Molm14 | ITD | 0.72 |
| HB-11;19 | PM | 4.24 |
| Ba/F3-D835Y | PM | 1.74 |
| SEM-K2 | WT (overexpressed with autocrine activation) | 3.45 |
| REH | WT | 112 |
| HL60 | No expression | 138.3 |
| K562 | No expression | >200 |
Proliferation IC50 (nM) measured after 48 hours of drug exposure (0 to 200 nM) in RPMI-1640 with 10% fetal bovine serum, relative to DMSO control, as in Figure 2A.